Medtronic plc 's MDT brain therapy business gets a boost with the recent FDA approval for the company's latest Deep Brain Stimulation (DBS) Clinician.

--Medtronic plc, the global leader in medical technology, today announced the CE Mark for the SenSight™ directional lead system for Deep Brain Stimulation therapy as treatment of symptoms ...

Having to manually program settings can be a time-consuming process. Medtronic’s SureTune2 aims to alleviate some of the frustrations of this process. Using visualization of patient-specific ...

The U.S. FDA approval also includes the Medtronic BrainSense™ Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings.

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.

To help clinicians and patients better optimize the therapy, Medtronic sought user-friendly mobile devices to adjust the programming of DBS implants and to put more control into the patient’s hands.

Medtronic has recalled the auto-registration feature in the StealthStation deep brain stimulation (DBS) software because of inaccuracies during DBS procedures, according to a notice on the US Food ...

Medtronic's new deep brain stimulation device, Percept, reads brain signals to better optimize treatment. Traditionally, physicians adjust DBS signals based on a patient’s diary entries, which ...

The SenSight directional DBS lead system works seamlessly with certain Medtronic neurostimulators, including the recently-approved Percept™ PC neurostimulator.